Yale SPORE in Lung Cancer Career Enhancement Program
耶鲁 SPORE 肺癌职业提升计划
基本信息
- 批准号:10203858
- 负责人:
- 金额:$ 7.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-26 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAppointmentAreaAwardBasic ScienceBiochemistryBiologicalBiophysicsCancer BiologyCollaborationsColon CarcinomaCommunitiesDevelopmentDiagnosisDisciplineFacultyFellowship ProgramFosteringFoundationsFundingGenerationsGeneticGoalsGrowthHumanInfrastructureInstitutionMalignant neoplasm of lungMalignant neoplasm of prostateMalignant neoplasm of thoraxMedicalMedical OncologyMedical ResearchMentorsMinority RecruitmentMolecularPathologyPatientsPharmacologyPhysiciansPreventionProceduresProcessPulmonologyResearchResearch PersonnelScienceScientistSeedsSolidTalentsTrainingTranslational ResearchUnited States National Institutes of HealthWorkYale Cancer Centeranticancer researchbasecareerclinical centerclinical investigationdesigninterestknowledge basemalignant breast neoplasmmedical schoolsnext generationnovelpersonalized medicineprogramsrecruittranslational impacttranslational research programtranslational scientist
项目摘要
PROGRAM SUMMARY
The number of physician-scientists working in lung cancer has not kept pace with the overall growth of the
medical research community or with the growth in our basic knowledge base, resulting in an increasing number
of unrealized basic and translational research opportunities. Yale is uniquely suited to helping rebuild this base
with our strong commitment to translational research. The Career Enhancement Program (CEP) of the Yale
SPORE in Lung Cancer (YSILC) has been designed to contribute substantively to ongoing efforts and new
initiatives attempting to address this problem. The goal of the CEP is to educate a new generation of
investigators committed to translational research in lung cancer. The CEP has substantial institutional
commitment, both in terms of funding and infrastructure. For example, our translational research office at Yale
(also led by Dr. Herbst, YSILC PI) has been committed to providing early seed funding and translational
support to young investigators early in their research careers. Potential CEP candidates include promising
junior faculty who are interested in establishing their careers in translational lung cancer research and/or
established investigators whose previous research has been in other areas and would like to transition into
lung cancer focused research. Junior faculty awardees will be paired with mentors who are more established
lung cancer investigators with a documented record of successful mentoring. In this way, the YSILC will
stimulate the development of the next generation of physician scientists, addressing the most challenging
issues in lung cancer research.
计划概要
研究肺癌的医师科学家数量并没有跟上肺癌总体增长的步伐
医学研究界或随着我们基础知识库的增长,导致越来越多的
未实现的基础和转化研究机会。耶鲁大学非常适合帮助重建这个基地
我们对转化研究的坚定承诺。耶鲁大学职业提升计划(CEP)
SPORE in Lung Cancer (YSILC) 旨在为正在进行的努力和新的研究做出实质性贡献
试图解决这个问题的举措。 CEP 的目标是教育新一代
研究人员致力于肺癌的转化研究。 CEP 拥有大量的机构
资金和基础设施方面的承诺。例如,我们在耶鲁大学的转化研究办公室
(同样由 YSILC PI Herbst 博士领导)一直致力于提供早期种子资金和转化
在年轻研究人员的研究生涯早期提供支持。潜在的 CEP 候选者包括有前途的
有兴趣在转化肺癌研究领域建立自己的职业生涯的初级教师和/或
已建立的研究人员,其先前的研究已在其他领域进行,并希望过渡到
肺癌重点研究。初级教师获奖者将与更有经验的导师配对
具有成功指导记录的肺癌研究人员。这样,YSILC 将
刺激下一代医师科学家的发展,解决最具挑战性的问题
肺癌研究中的问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harriet M. Kluger其他文献
Clonal determinants of organotropism and survival in metastatic uveal melanoma
转移性葡萄膜黑色素瘤器官趋向性和生存的克隆决定因素
- DOI:
10.1101/2024.05.14.593919 - 发表时间:
2024-05-15 - 期刊:
- 影响因子:0
- 作者:
Bailey S.C.L. Jones;Patrick C. Demkowicz;Mitchelle Matesva;Renelle Pointdujour Lim;John H. Sinard;Antonietta Bacchiocchi;Ruth Halaban;M. Bosenberg;Mario Sznol;Harriet M. Kluger;Mathieu F. Bakhoum - 通讯作者:
Mathieu F. Bakhoum
Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer
HuR对乳腺癌中含有非AU丰富元件的c-fms原癌基因表达的调控
- DOI:
10.1038/onc.2008.469 - 发表时间:
2009-03-05 - 期刊:
- 影响因子:8
- 作者:
H. Woo;Yi Zhou;Xiaofang Yi;C. L. David;Wenxin Zheng;Maureen Gilmore;Harriet M. Kluger;E. C. Ulukus;T. Baker;Jha'nae B. Stoffer;S. Chambers - 通讯作者:
S. Chambers
Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
生长因子受体结合蛋白 7 (Grb7) 作为乳腺癌的预后标志物和治疗靶点。
- DOI:
10.1093/annonc/mdp346 - 发表时间:
2010-03-01 - 期刊:
- 影响因子:0
- 作者:
Yasmine Nadler;A. M. González;A. M. González;R. Camp;D. Rimm;Harriet M. Kluger;Y. Kluger - 通讯作者:
Y. Kluger
Patterns of brain metastases response to immunotherapy with pembrolizumab.
脑转移瘤对派姆单抗免疫治疗的反应模式。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:3.9
- 作者:
Amit Mahajan;Sarah L Goldberg;Sarah A Weiss;Thuy Tran;Kanwar Singh;Kavita Joshi;Mariam S Aboian;Harriet M. Kluger;Veronica L Chiang - 通讯作者:
Veronica L Chiang
A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
一项针对切除的高危黑色素瘤进行辅助 ipilimumab(3 或 10 mg/kg)与高剂量干扰素 alfa-2b 的 III 期随机研究(美国组间 E1609):ipilimumab 组的初步安全性和有效性。
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:0
- 作者:
A. Tarhini;Sandra J. Lee;F. Hodi;Uma N. Rao;Gary Irvin Cohen;O. Hamid;Laura Fulper Hutchins;J. Sosman;Harriet M. Kluger;V. Sondak;H. Koon;Donald P. Lawrence;Kari Kendra;D. Minor;Carrie B. Lee;M. Albertini;Lawrence E. Flaherty;T. M. Petrella;John M. Kirkwood - 通讯作者:
John M. Kirkwood
Harriet M. Kluger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harriet M. Kluger', 18)}}的其他基金
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy
双同位素 SPECT 成像和免疫细胞免疫表型分析以确定对免疫治疗的反应
- 批准号:
10590408 - 财政年份:2023
- 资助金额:
$ 7.98万 - 项目类别:
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM
耶鲁大学癌症中心卡拉布雷西免疫肿瘤学培训计划
- 批准号:
10646793 - 财政年份:2018
- 资助金额:
$ 7.98万 - 项目类别:
The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)
耶鲁大学癌症中心卡拉布雷西免疫肿瘤学培训计划 (IOTP)
- 批准号:
9899739 - 财政年份:2018
- 资助金额:
$ 7.98万 - 项目类别:
A research and training program for junior clinicians in treating metastatic mela
初级临床医生治疗转移性黄斑变性的研究和培训计划
- 批准号:
8581535 - 财政年份:2013
- 资助金额:
$ 7.98万 - 项目类别:
A research and training program for junior clinicians in treating metastatic mela
初级临床医生治疗转移性黄斑变性的研究和培训计划
- 批准号:
8692684 - 财政年份:2013
- 资助金额:
$ 7.98万 - 项目类别:
A research and training program for junior clinicians in treating metastatic mela
初级临床医生治疗转移性黄斑变性的研究和培训计划
- 批准号:
9279067 - 财政年份:2013
- 资助金额:
$ 7.98万 - 项目类别:
Models to predict prognosis and benefit from adjuvant therapy in renal cell carci
预测肾细胞癌预后和辅助治疗获益的模型
- 批准号:
8236884 - 财政年份:2011
- 资助金额:
$ 7.98万 - 项目类别:
Models to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell Carci
预测肾细胞癌预后和辅助治疗获益的模型
- 批准号:
8613470 - 财政年份:2011
- 资助金额:
$ 7.98万 - 项目类别:
Models to predict prognosis and benefit from adjuvant therapy in renal cell carci
预测肾细胞癌预后和辅助治疗获益的模型
- 批准号:
8444714 - 财政年份:2011
- 资助金额:
$ 7.98万 - 项目类别:
Models to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell Carci
预测肾细胞癌预后和辅助治疗获益的模型
- 批准号:
8613470 - 财政年份:2011
- 资助金额:
$ 7.98万 - 项目类别:
相似国自然基金
面向集卡预约环境的港口集疏运道路作业计划与管控方法
- 批准号:52372303
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
面向一站式预约的门诊患者多检查动态调度优化研究
- 批准号:72371200
- 批准年份:2023
- 资助金额:41 万元
- 项目类别:面上项目
考虑患者等待时长的医疗系统预约调度研究:基于近似动态规划的方法
- 批准号:72272027
- 批准年份:2022
- 资助金额:45 万元
- 项目类别:面上项目
基于集卡预约扰动致因解构的港口集疏运通道空间尺度优化研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
数据驱动下港口集卡预约系统的预约配额方案优化与失约车辆再预约策略研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A Novel Algorithm to Identify People with Undiagnosed Alzheimer's Disease and Related Dementias
一种识别未确诊阿尔茨海默病和相关痴呆症患者的新算法
- 批准号:
10696912 - 财政年份:2023
- 资助金额:
$ 7.98万 - 项目类别:
Examining linkages between disrupted care and chronic disease outcomes during the COVID-19 pandemic: a VAMC level spatio-temporal analysis
检查 COVID-19 大流行期间中断的护理与慢性病结果之间的联系:VAMC 级别时空分析
- 批准号:
10641136 - 财政年份:2023
- 资助金额:
$ 7.98万 - 项目类别:
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)Scientific Leadership Center; ADMIN SUPPLEMENT
艾滋病毒/艾滋病干预青少年医学试验网络 (ATN) 科学领导中心;
- 批准号:
10855435 - 财政年份:2023
- 资助金额:
$ 7.98万 - 项目类别:
Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory
密苏里大学区域生物防护实验室 NIH/NIAID 高优先级病原体研究的资源和劳动力发展
- 批准号:
10793827 - 财政年份:2023
- 资助金额:
$ 7.98万 - 项目类别:
PARCA (a digital tool) to improve Justice and Health
PARCA(数字工具)改善司法和健康
- 批准号:
10483296 - 财政年份:2023
- 资助金额:
$ 7.98万 - 项目类别: